Limited Competition: Renewal of Diabetes Prevention Program Outcomes Study - Phase 2 (U01)

The summary for the Limited Competition: Renewal of Diabetes Prevention Program Outcomes Study - Phase 2 (U01) grant is detailed below. This summary states who is eligible for the grant, how much grant money will be awarded, current and past deadlines, Catalog of Federal Domestic Assistance (CFDA) numbers, and a sampling of similar government grants. Verify the accuracy of the data FederalGrants.com provides by visiting the webpage noted in the Link to Full Announcement section or by contacting the appropriate person listed as the Grant Announcement Contact. If any section is incomplete, please visit the website for the National Institutes of Health, which is the U.S. government agency offering this grant.

Limited Competition: Renewal of Diabetes Prevention Program Outcomes Study - Phase 2 (U01): -Purpose. The purpose of this limited competition is to continue patient follow-up of the original Diabetes Prevention Program (DPP) cohort through a Diabetes Prevention Program Outcomes Study (DPPOS) Phase 2 cooperative agreement. The DPPOS Phase 2 extends an initial DPP follow-up, the DPPOS. The DPP was a multicenter placebo controlled clinical trial examining the efficacy of treatments to prevent or delay the development of Type 2 diabetes in a population at high risk, owing to the presence of impaired glucose tolerance (IGT). The DPP demonstrated that lifestyle and drug (metformin) interventions compared to control could reduce the development of Type 2 diabetes by 58% and 31% respectively. The study ended one year early and 86% of the DPP cohort was enrolled in the DPPOS follow-up study designed to determine the longer-term effects of the DPP interventions. Although prevention/delay of diabetes should be associated with decreased disease burden over time, the actual impact is not known. The DPPOS Phase 2 will continue the DPPOS follow-up of long-term effects of the DPP interventions on 1) Further diabetes development, 2) Microvascular outcomes and 3) Cardiovascular Disease (CVD) and CVD risk factors. The extension of DPPOS will also include epidemiologic analysis of Impaired Glucose Tolerance (IGT) and new-onset type 2 and determination of the economic impact of diabetes prevention/delay. -Mechanism of Support. This FOA will utilize the cooperative agreement (U01) grant mechanism. -Funds Available and Anticipated Number of Awards. The NIDDK intends to commit approximately $14.0 million in FY 2009 to make 21 clinical center awards and 1 Coordinating Center award.